← Human Trials & Peer-Reviewed Studies
Paracrine regulation of growth hormone secretion by estrogen in women.
Plain-language guide to PMID 20444909 (2010): open-label and crossover clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 20444909
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2010
- Study type
- Clinical Trial
- Authors
- Birzniece V et al. (4 authors)
- DOI
- 10.1210/jc.2010-0476
What This Study Did, in Plain Language
What Was Tested
This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The aim was to investigate whether local estrogens produced from aromatization regulate GH secretion.
Why It Was Studied
Paracrine regulation is emerging as a discrete control mechanism in the endocrine system.
In hypogonadal men, stimulation of GH secretion by testosterone requires prior aromatization to estradiol, a paracrine effect unmasked by central estrogen receptor blockade with tamoxifen.
Who Took Part
The age groups tagged for this paper are middle-aged adults, older adults and people over 80, women only.
The researchers compared the effects on GH secretion of tamoxifen with estradiol valerate in postmenopausal women.
How the Study Was Run
The design is described as open-label and crossover.
Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.
In the crossover set-up each of the participants took both Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison in turn, acting as their own control.
The researchers conducted an open-label, two-phase, crossover study.
What Was Measured
In hypogonadal men, stimulation of GH secretion by testosterone requires prior aromatization to estradiol, a paracrine effect unmasked by central estrogen receptor blockade with tamoxifen.
PubMed files the paper under topics including Analysis of Variance, Arginine, Estradiol, Human Growth Hormone, Insulin-Like Growth Factor I, Paracrine Communication and Postmenopause.
What This Means in Plain Language
The paper is an open-label and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.